Latest Manufacturing News

Papyrus Australia reported a $52,000 operating cash outflow for April 2025 but bolstered its liquidity with $239,000 in financing inflows, extending its funding runway to over a year.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Merchant House International Limited reported a 38% reduction in net loss for FY2025, driven by asset sales and operational wind-down. The company is moving towards divesting remaining assets, delisting from ASX, and winding up.

Cardiex Limited has raised $2.4 million through an institutional placement and launched a fully underwritten entitlement offer to raise up to $4.1 million, aiming to scale its CONNEQT Pulse device.

F.F.I. Holdings Ltd anticipates a substantial uplift in its property valuations as of June 2025, driven by rising asset values in both investment and own-use properties.

RareX Limited has partnered with Gega Elements to develop Australia’s inaugural integrated gallium supply chain, aiming to reduce reliance on Chinese supply and boost national critical mineral resilience.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

QEM Limited has raised A$2.05 million through a strongly supported placement to accelerate its Julia Creek Vanadium and Energy Project, coinciding with the retirement of founding CEO Gavin Loyden and the appointment of Robert Cooper as his successor.

Elsight Limited has expanded its supply agreement with a European defence drone OEM to a total of US$9.63 million for 2025, positioning the company for profitability and cash flow break-even this year.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

BP8 has completed its inaugural shipment of Indonesian seaweed biomass to South Korean manufacturer MSC, Ltd., under a new sales cooperation agreement with PT Kebula Raya Bestari. This initial contract signals BP8’s growing footprint in the global seaweed supply chain.

European Lithium Limited has clarified its mineral resource estimates and production targets for the Tanbreez Project following an ASX compliance query, reaffirming its basis for financial forecasts despite cautionary geological statements.